Comparative Pharmacology
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus CLINORIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAMINOPHEN AND IBUPROFEN versus CLINORIL.
ACETAMINOPHEN AND IBUPROFEN vs CLINORIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, and antipyretic effects. Sulindac is a prodrug converted to the active sulfide metabolite.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
150-200 mg orally twice daily, with maximum daily dose of 400 mg.
None Documented
None Documented
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
7.8 hours (terminal); clinical context: prolonged in elderly and renal impairment, requiring dose adjustment.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Renal: 50% as unchanged drug, 25% as glucuronide conjugate; Biliary/Fecal: 25% as metabolites.
Category D/X
Category C
NSAID
NSAID